Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estriol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 5/20 | 0.89 |
| ▸ | ESR2 known ✓ | Q92731 | 4/20 | 0.89 |
| ▸ | LMNA | P02545 | 4/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.89 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.89 |
| ▸ | SHBG | P04278 | 2/20 | 0.89 |
| ▸ | PGR | P06401 | 2/20 | 0.89 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.89 |
| ▸ | AR | P10275 | 2/20 | 0.89 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.89 |
| ▸ | SNCA | P37840 | 2/20 | 0.89 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.89 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.89 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.89 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.89 |
| ▸ | HSD17B1 | P14061 | 6/20 | 0.65 |
| ▸ | STS | P08842 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estriol SCHEMBL28444514 | 1.00 | ESR1 (0.89) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL7989770 | 1.00 | ESR1 (0.89) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL223226 | 0.94 | ESR1 (1.00) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL8941750 | 0.94 | ESR1 (1.00) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL2001122 | 0.94 | ESR1 (1.00) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL23743979 | 0.94 | ESR1 (1.00) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL223196 | 0.94 | ESR1 (1.00) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL4896486 | 0.94 | ESR1 (1.00) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL14373308 | 0.94 | ESR1 (1.00) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Epiestriol SCHEMBL221084 | 0.94 | ESR1 (1.00) | ESR1ESR2LMNACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043943-A1 | Method for the management of incontinence | ALZA CORPORATION | 2004-03-04 | — | — | US | claimed |
| US-20040037881-A1 | Method for the management of incontinence | ALZA CORPORATION | 2004-02-26 | — | — | US | claimed |
| US-6262115-B1 | ADMITTING ORALLY INTO THE PATIENT A DOSAGE FORM OF OXYBUTYNIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALT, THAT IS ADMINISTERED ONCE-A-DAY AS SUSTAINED-RELEASE FORM FOR MANAGEMENT OF INCONTINENCE | ALZA COPORATION | 2001-07-17 | — | — | US | claimed |
| US-20010005728-A1 | Method for the management of incontinence | ALZA CORPORATION | 2001-06-28 | — | — | US | claimed |
| EP-0500793-B1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORP (US) | 1993-11-03 | — | — | EP | claimed |
| EP-0472645-B1 | OSMOTIC DOSAGE FORM | ALZA CORPORATION (US) | 1993-07-14 | — | — | EP | claimed |
| US-5200197-A | Contraceptive pill | ALZA CORPORATION (US) | 1993-04-06 | — | — | US | claimed |
| EP-0500793-A1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL. | ALZA CORP (US) | 1992-09-02 | — | — | EP | claimed |
| US-5098714-A | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORPORATION (US) | 1992-03-24 | — | — | US | claimed |
| EP-0472645-A1 | OSMOTIC DOSAGE FORM. | ALZA CORP (US) | 1992-03-04 | — | — | EP | claimed |
| WO-1991007173-A1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORPORATION (US) | 1991-05-30 | — | — | WO | claimed |
| WO-1990014075-A1 | OSMOTIC DOSAGE FORM | ALZA CORPORATION (US) | 1990-11-29 | — | — | WO | claimed |
| US-4948593-A | SUSTAINED AND CONTROLLED CONTRACEPTION | ALZA CORPORATION (US) | 1990-08-14 | — | — | US | claimed |
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | VAN BOGAERT GINA (BE) | 2026-01-15 | — | — | US | disclosed |
| WO-2023223235-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | PURNA PHARMACEUTICALS NV (BE) | 2023-11-23 | — | — | WO | disclosed |
| WO-2015161078-A1 | METHODS FOR COMPREHENSIVE PROFILING OF STEROID METABOLOME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-1990014075-A1 | OSMOTIC DOSAGE FORM | ALZA CORPORATION (US) | 1990-11-29 | — | — | WO | disclosed |
| US-4952569-A | ESTRADIOL GLYCIDYL ETHERS FOR USE IN IMMUNOASSAYS; IMMOBILIZATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-08-28 | — | — | US | disclosed |
| US-4948593-A | SUSTAINED AND CONTROLLED CONTRACEPTION | ALZA CORPORATION (US) | 1990-08-14 | — | — | US | disclosed |
| EP-0200960-A1 | Total estriol fluorescence polarization immunoassay | ABBOTT LABORATORIES (US) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | NR5A1, SHBG, GNRHR | ESR1 188/4885ESR2 274/4885LMNA 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.